These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 27320409)
1. Orgasm, Serotonin Reuptake Inhibition, and Plasma Oxytocin in Obsessive-Compulsive Disorder. Gleaning From a Distant Randomized Clinical Trial. Humble MB; Bejerot S Sex Med; 2016 Sep; 4(3):e145-55. PubMed ID: 27320409 [TBL] [Abstract][Full Text] [Related]
2. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study. Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174 [TBL] [Abstract][Full Text] [Related]
3. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308 [TBL] [Abstract][Full Text] [Related]
4. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Simpson HB; Foa EB; Liebowitz MR; Ledley DR; Huppert JD; Cahill S; Vermes D; Schmidt AB; Hembree E; Franklin M; Campeas R; Hahn CG; Petkova E Am J Psychiatry; 2008 May; 165(5):621-30. PubMed ID: 18316422 [TBL] [Abstract][Full Text] [Related]
5. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Muscatello MR; Bruno A; Pandolfo G; Micò U; Scimeca G; Romeo VM; Santoro V; Settineri S; Spina E; Zoccali RA J Clin Psychopharmacol; 2011 Apr; 31(2):174-9. PubMed ID: 21346614 [TBL] [Abstract][Full Text] [Related]
6. Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial. Foa EB; Simpson HB; Gallagher T; Wheaton MG; Gershkovich M; Schmidt AB; Huppert JD; Imms P; Campeas RB; Cahill S; DiChiara C; Tsao SD; Puliafico A; Chazin D; Asnaani A; Moore K; Tyler J; Steinman SA; Sanches-LaCay A; Capaldi S; Snorrason Í; Turk-Karan E; Vermes D; Kalanthroff E; Pinto A; Hamlett GE; Middleton R; Hahn CG; Xu B; Van Meter PE; Katechis M; Rosenfield D JAMA Psychiatry; 2022 Mar; 79(3):193-200. PubMed ID: 35080598 [TBL] [Abstract][Full Text] [Related]
7. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. Denys D; Van Nieuwerburgh F; Deforce D; Westenberg HG J Clin Psychiatry; 2007 May; 68(5):747-53. PubMed ID: 17503984 [TBL] [Abstract][Full Text] [Related]
8. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. Denys D; van Megen HJ; van der Wee N; Westenberg HG J Clin Psychiatry; 2004 Jan; 65(1):37-43. PubMed ID: 14744166 [TBL] [Abstract][Full Text] [Related]
9. Issues in the pharmacological treatment of obsessive-compulsive disorder. Math SB; Janardhan Reddy YC Int J Clin Pract; 2007 Jul; 61(7):1188-97. PubMed ID: 17511795 [TBL] [Abstract][Full Text] [Related]
10. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Foa EB; Liebowitz MR; Kozak MJ; Davies S; Campeas R; Franklin ME; Huppert JD; Kjernisted K; Rowan V; Schmidt AB; Simpson HB; Tu X Am J Psychiatry; 2005 Jan; 162(1):151-61. PubMed ID: 15625214 [TBL] [Abstract][Full Text] [Related]
11. Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials. Romanelli RJ; Wu FM; Gamba R; Mojtabai R; Segal JB Depress Anxiety; 2014 Aug; 31(8):641-52. PubMed ID: 24390912 [TBL] [Abstract][Full Text] [Related]
12. Impact of brain-derived neurotrophic factor Val66Met polymorphism and response to escitalopram or paroxetine in obsessive-compulsive disorder. Harika-Germaneau G; Langbour N; Patri S; Solinas M; Chatard A; Millet B; Hashemian F; Pérault-Pochat MC; Jaafari N; Lafay-Chebassier C CNS Spectr; 2022 Oct; 27(5):645-651. PubMed ID: 34313207 [TBL] [Abstract][Full Text] [Related]
16. Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice. Shanahan NA; Velez LP; Masten VL; Dulawa SC Biol Psychiatry; 2011 Dec; 70(11):1039-48. PubMed ID: 21920503 [TBL] [Abstract][Full Text] [Related]
17. Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. Afshar H; Akuchekian S; Mahaky B; Zarean E J Res Med Sci; 2014 Oct; 19(10):976-81. PubMed ID: 25538783 [TBL] [Abstract][Full Text] [Related]
18. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Stein DJ; Andersen EW; Tonnoir B; Fineberg N Curr Med Res Opin; 2007 Apr; 23(4):701-11. PubMed ID: 17407626 [TBL] [Abstract][Full Text] [Related]
19. Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy. Stein DJ; Carey PD; Lochner C; Seedat S; Fineberg N; Andersen EW CNS Spectr; 2008 Jun; 13(6):492-8. PubMed ID: 18567973 [TBL] [Abstract][Full Text] [Related]
20. Optimal Dose of Serotonin Reuptake Inhibitors for Obsessive-Compulsive Disorder in Adults: A Systematic Review and Dose-Response Meta-Analysis. Xu J; Hao Q; Qian R; Mu X; Dai M; Wu Y; Tang Y; Xie M; Wang Q Front Psychiatry; 2021; 12():717999. PubMed ID: 34630180 [No Abstract] [Full Text] [Related] [Next] [New Search]